Advertisement

Malignant syndrome triggered by influenza A virus infection in a patient with Parkinson’s disease with improvement after intravenous peramivir treatment

  • Kosuke MatsuzonoEmail author
  • Masamichi Baba
  • Goro Imai
  • Hiroaki Imai
  • Shigeru Fujimoto
Letter to the Editor
  • 26 Downloads

Introduction

Malignant syndrome, also called parkinsonism-hyperpyrexia syndrome, is a rare medical emergency in patients with Parkinson’s disease (PD). The precipitating events that trigger malignant syndrome in patients with PD are anti-parkinsonian drug withdrawal and stress-related factors [1, 2]. Infection is a major cause of malignant syndrome, and fever is considered the trigger [1]. However, the relationship among malignant syndrome, influenza virus infection, and treatment for influenza virus remains unclear. We herein report a case involving a man with PD who developed malignant syndrome secondary to influenza A virus infection but improved after intravenous peramivir treatment without dantrolene.

Case presentation

A 71-year-old man had an 8-year history of Hoehn–Yahr stage ΙΙΙ PD and lived at home with his wife. His gait was slightly unstable, but he was able to walk independently without a cane. His Movement Disorder Society (MDS)-sponsored revision of the Unified...

Notes

Acknowledgements

We appreciate the cooperation of the patient. We also thank Angela Morben, DVM, ELS, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Authors’ contributions

K.M., M.B., G. I, and H.I. were the attending doctors in the present case. K.M. drafted the manuscript. S.F. conceived the study, participated in its coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical standards

Informed consent was obtained from the patient described in this article.

References

  1. 1.
    Hashimoto T, Tokuda T, Hanyu N, Tabata K, Yanagisawa N (2003) Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson's disease. Parkinsonism Relat Disord 9(Suppl 1):S25–S30CrossRefGoogle Scholar
  2. 2.
    Ogawa E, Sakakibara R, Kishi M, Tateno F (2012) Constipation triggered the malignant syndrome in Parkinson's disease. Neurol Sci 33:347–350CrossRefGoogle Scholar
  3. 3.
    Levenson JL (1985) Neuroleptic malignant syndrome. Am J Psychiatry 142:1137–1145CrossRefGoogle Scholar
  4. 4.
    Takubo H, Harada T, Hashimoto T et al (2003) A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord 9(Suppl 1):S31–S41CrossRefGoogle Scholar
  5. 5.
    Lattanzi L, Mungai F, Romano A, Bonuccelli U, Cassano GB, Fagiolini A (2006) Subcutaneous apomorphine for neuroleptic malignant syndrome. Am J Psychiatry 163:1450–1451CrossRefGoogle Scholar
  6. 6.
    Cox B, Lee TF (1977) Do central dopamine receptors have a physiological-role in thermoregulation. Br J Pharmacol 61:83–86CrossRefGoogle Scholar
  7. 7.
    Shetty AK, Peek LA (2012) Peramivir for the treatment of influenza. Expert Rev Anti-Infect Ther 10:123–143CrossRefGoogle Scholar
  8. 8.
    Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T (2012) Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 56:369–377CrossRefGoogle Scholar

Copyright information

© Fondazione Società Italiana di Neurologia 2019

Authors and Affiliations

  1. 1.Department of Internal MedicineImai HospitalTochigiJapan
  2. 2.Division of Neurology, Department of Internal MedicineJichi Medical University School of MedicineTochigiJapan

Personalised recommendations